Perceptual Learning computer-based therapy improves BCVA and CSF in stable keratoconus patients and improves uncorrected vision in post-cataract patients with multifocal IOL implants. Surgeons should consider this as a post-operative therapeutic adjuvant.

RevitalVision is a SaaS-based, digital health startup headquartered in Israel. We offer a unique solution to millions with poor or insufficient vision whose needs are unmet by existing vision treatments. Our non-invasive technology enhances eyesight neurologically. We utilize brain science and a proprietary algorithm to effectively stimulate the brain’s visual cortex to improve vision. Our technology has been clinically validated to enhance vision outcomes with long-lasting results in a wide range of eye diseases and vision impairments, with a significant impact on vision and quality of life. Our product – a home-based vision-training software program operates directly from a standard web browser on any personal computer, without the need for any special hardware. Our customers include: 1) Eyecare professionals (B2B) who prescribe the home-based treatment with our software for specific conditions such as amblyopia (lazy eye) and low vision, and 2) Consumers (B2C) seeking wellness and post-surgery solutions, beyond available treatments.

Our technology is the only FDA-cleared product with an efficacy claim to improve vision in amblyopia (Lazy eye) in patients age 9 or older and is CE Marked with a broad intent for use – to improve vision above age 9.

In the past year, 3 new RCTs have demonstrated the efficacy of RevitalVision in improving vision in keratoconus patients.

All three studies demonstrated statistically significant clinical outcomes with an average improvement of 1.7-2.8 LogMar lines in distance BCVA. Many participants experienced notable improvement in their subjective vision and life quality.

1. An RCT recently published in AJO demonstrated an average improvement of 1.7 LogMar lines in best spectacle-corrected vision in non-progressing keratoconus patients who are intolerant to CL.
2. An RCT presented at the recent ASCRS meeting in Boston demonstrated a 2.5 LogMar lines improvement in BCVA and a 100% improvement in contrast sensitivity in stable keratoconus patients post-crosslinking.
3. A new RCT from Shamir Medical Center on non-progressing keratoconus patients with poor BCVA (20/40-20/100) was accepted for live presentation at the upcoming ASCRS meeting in Los Angeles. The average improvement in BCVA was 2.8 LogMar lines for distance and 3 LogMar lines for near, and the average improvement in contrast sensitivity was 100%.

This new accumulated evidence should encourage corneal specialists to offer this advanced, non-invasive, and non-risk therapy to keratoconus patients, who have already maximized their treatment options but are still unhappy with their vision.